BLA

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (ADR) (NYSE: SNY) jointly announced Friday morning that the U.S. Food and Drug Administration has accepted for review the Biologics License Application (BLA) for sarilumab. Regeneron noted that the BLA for sarilumab contains data from...

Shares of Vericel Corp (NASDAQ: VCEL), a developer of cellular therapies for use in the treatment of patients with diseases and conditions, were trading higher by nearly 4 percent on Tuesday morning. The move higher in Vericel's stock follows the company's announcement on Monday that it has...